Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Eli Tran,Chinmay Jani,Nicole Zhang,Jill Tsai,Elizabeth Pan,Justine Panian,Rana R. McKay

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.205

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:205 Background: Next-generation sequencing (NGS) of ctDNA is a novel technology that can complement tumor tissue NGS and has the potential to inform prognosis, treatment (tx) selection, and real time evolution of tumor molecular alterations. While tx options for pts with mCRPC have advanced, tx resistance is inevitable. Our real-world evidence study aims to evaluate longitudinal molecular changes in ctDNA following systemic tx to inform sequential tx strategies for pts with mCRPC. Methods: We interrogated data from GuardantINFORM, a clinical-genomics database with ctDNA molecular information and structured commercial payer-claims data. We conducted genetic mutations analysis in pts diagnosed with prostate cancer both before and after Androgen Receptor Signaling Inhibitors (ARSi), Poly(ADP‐ribose) Polymerase Inhibitors (PARPi), and taxanes. The post-tx analysis was performed on samples collected within 3 months of tx discontinuation prior to initiation of a subsequent tx as a proxy of disease progression. Mann-Whitney test was conducted to assess the differences in mutations observed pre and post tx. We also examined the association between ctDNA burden and overall survival (OS). Results: Overall, from a database of 21,682 patients with prostate cancer, following the above filters, we analyzed 145 pts with paired pre / post-ARSI, 54 with paired pre / post-PARPi, and 115 with paired pre / post-taxane samples. Table highlights the most commonly altered genes prevalent in post-tx samples. The most frequent (%pre/%post) AR alterations post-ARSI included AR amplifications (11%/23%), AR T878A (5%/9%), AR L702H (2%/6%), AR H875Y (0.7%/1.4%), and AR F877L (0%/1.4%). The most frequent HRR alterations post PARPi included ATM (25%/25%), BRCA2 (25%/18%), BRCA1 (3%/5%), CDK12 (6%/5%), and PALB2 (3%/2%). All three tx exhibited a significantly higher prevalence of mutations post-tx (mean increase in alterations 0.3-1.3, p<0.001 for all tx). Pts with higher ctDNA burden in pre-tx samples had worse OS compared to pts with low or undetectable burden. Conclusions: Our study revealed dynamic shifts in genetic mutations in pts with mCRPC following ARSi, PARPi and taxanes. Additionally, we highlight the prognostic significant of ctDNA burden in mCRPC. These data can help inform personalized sequential tx strategies for pts with mCRPC. [Table: see text]

oncology